Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03984565 · ClinicalTrials.gov registry record · Phase 2
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
A Phase 2 study of Chronic Pain, sponsored by Staci Gruber, Ph.D..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03984565: Recruiting Phase 2 study of Chronic Pain, sponsored by Staci Gruber, Ph.D..
NCT03984565 is a Phase 2 study of Chronic Pain that is actively recruiting participants, run by Staci Gruber, Ph.D.. The registered enrollment target is 25 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03984565, a Phase 2 study of Chronic Pain, is actively recruiting participants, sponsored by Staci Gruber, Ph.D..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.
Primary Outcome
The NRS is an 11-point scale on which subjects rate their pain by choosing a number between 0 (no pain) and 10 (worst possible pain). Lower scores indicate less pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT03984565 shows while recruiting
NCT03984565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03984565 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03984565 about?
NCT03984565 is a clinical study titled "PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product". This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and bioma...
What is the current status of trial NCT03984565?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-06-27. Estimated completion is 2026-09.
What conditions does trial NCT03984565 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT03984565?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03984565?
This trial is sponsored by Staci Gruber, Ph.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03984565 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03984565's enrollment target sits among peer trials
25 257th of 301 higher than 39 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
-
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI